Maxim Group Reiterates Buy on Viking Therapeutics, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a $120 price target.
March 15, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group analyst Naz Rahman reiterates a Buy rating on Viking Therapeutics with a maintained price target of $120.
The reiteration of a Buy rating and the maintenance of a high price target ($120) by a reputable analyst could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100